CD40L deficiency protects against aneurysm formation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 38, Issue 5, 2018, Pages 1076-1085

  Kusters, Pascal J H ^g   Seijkens, Tom T P ^a,g   Beckers, Linda ^g   Lievens, Dirk ^a,g   Winkels, Holger ^a,g   De Waard, Vivian ^g   Duijvestijn, Adriaan ^b   Liljeqvist, Moritz Lindquist ^c   Roy, Joy ^b   Daugherty, Alan ^d   Newby, Andrew ^e   Gerdes, Norbert ^a,f   Lutgens, Esther ^a,g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Aneurysms; Angiotensin II; Cytokines; Inflammation; Matrix metalloproteinase 9

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE; COLLAGENASE 3; CXCL2 CHEMOKINE; CYTOKINE; GELATINASE A; GELATINASE B; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; RANTES; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR FOXP3; ANGIOTENSIN II; MMP13 PROTEIN, MOUSE; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE;

ABDOMINAL AORTIC ANEURYSM; ANEURYSM; ANEURYSM RUPTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTERY WALL; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISSECTING ANEURYSM; ENZYME ACTIVITY; FATALITY; HELPER CELL; HUMAN; HUMAN TISSUE; INCIDENCE; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THROMBUS; TRANSCRIPTOMICS; ABDOMINAL AORTA; ANIMAL; AORTIC RUPTURE; APOLIPOPROTEIN E KNOCKOUT MOUSE; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; GENETICS; LESIONS AND DEFECTS; MALE; METABOLISM; PATHOLOGY;

ANEURYSM, DISSECTING; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; CD40 LIGAND; CHEMOKINES; CYTOKINES; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; MICE, KNOCKOUT, APOE; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 85060467423     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.310640     Document Type: Article

References (37)

1. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:92-102. doi: 10.1038/nrcardio.2010.180.
2. Ulug P, Powell JT, Sweeting MJ, Bown MJ, Thompson SG; SWAN Collaborative Group. Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women. Br J Surg. 2016;103:1097-1104. doi: 10.1002/bjs.10225.
3. Klink A, Hyafil F, Rudd J, et al. Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:338-347. doi: 10.1038/nrcardio.2011.1.
4. Romain M, Taleb S, Dalloz M, Ponnuswamy P, Esposito B, Pérez N, Wang Y, Yoshimura A, Tedgui A, Mallat Z. Overexpression of SOCS3 in T lymphocytes leads to impaired interleukin-17 production and severe aortic aneurysm formation in mice-brief report. Arterioscler Thromb Vasc Biol. 2013;33:581-584. doi: 10.1161/ATVBAHA.112. 300516.
5. Bhamidipati CM, Mehta GS, Moehle CW, Meher AK, Su G, Vigneshwar NG, Barbery C, Sharma AK, Kron IL, Laubach VE, Owens GK, Upchurch GR Jr, Ailawadi G. Adenosine 2A receptor modulates inflammation and phenotype in experimental abdominal aortic aneurysms. FASEB J. 2013;27:2122-2131. doi: 10.1096/fj.12-214197.
6. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994. doi: 10.1161/01.ATV.0000214999.12921.4f.
7. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432. doi: 10.1172/JCI38136.
8. Johnston WF, Salmon M, Su G, Lu G, Stone ML, Zhao Y, Owens GK, Upchurch GR Jr, Ailawadi G. Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:294-304. doi: 10.1161/ATVBAHA.112.300432.
9. Golledge AL, Walker P, Norman PE, Golledge J. A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers. 2009;26:181-188. doi: 10.3233/DMA-2009-0629.
10. Elmore JR, Keister BF, Franklin DP, Youkey JR, Carey DJ. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg. 1998;12:221-228. doi: 10.1007/s100169900144.
11. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost. 2009;102:206-214. doi: 10.1160/TH09-01-0029.
12. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for cd154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
13. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med. 2010;207:391-404. doi: 10.1084/jem.20091293.
14. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA. 2000;97: 7464-7469.
15. Mach F, Schönbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis. 1998;137(suppl):S89-S95.
16. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/ nar/gkv007.
17. Seijkens T, Kusters P, Engel D, Lutgens E. CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diab Vasc Dis Res. 2013;10:115-122. doi: 10.1177/1479164112455817.
18. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes athero-sclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612. doi: 10.1172/JCI7818.
19. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288(pt 1):93-99.
20. Guiducci C, Valzasina B, Dislich H, Colombo MP. CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol. 2005;35:557-567. doi: 10.1002/eji.200425810.
21. Xiong W, Zhao Y, Prall A, Greiner TC, Baxter BT. Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J Immunol. 2004;172:2607-2612.
22. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 2009;183:2741-2746. doi: 10.4049/jimmunol. 0803164.
23. Schönbeck U, Sukhova GK, Gerdes N, Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol. 2002;161:499-506. doi: 10.1016/S0002-9440(10)64206-X.
24. Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest. 2004;114:300-308. doi: 10.1172/JCI19855.
25. Zhou HF, Yan H, Cannon JL, Springer LE, Green JM, Pham CT. CD43-mediated IFN-γ production by CD8+ T cells promotes abdominal aortic aneurysm in mice. J Immunol. 2013;190:5078-5085. doi: 10.4049/jimmunol.1203228.
26. King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N, Hardy GJ, Owens AP 3rd, Howatt DA, Shen D, Tager AM, Luster AD, Daugherty A, Gerszten RE. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 2009;119:426-435. doi: 10.1161/CIRCULATIONAHA.108.785949.
27. Dietz HC. TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest. 2010;120:403-407. doi: 10.1172/JCI42014.
28. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, Michel JB, Vranckx R. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol. 2009;218:131-142. doi: 10.1002/path.2516.
29. Dai X, Shen J, Annam NP, Jiang H, Levi E, Schworer CM, Tromp G, Arora A, Higgins M, Wang XF, Yang M, Li HJ, Zhang K, Kuivaniemi H, Li L. SMAD3 deficiency promotes vessel wall remodeling, collagen fiber reorganization and leukocyte infiltration in an inflammatory abdominal aortic aneurysm mouse model. Sci Rep. 2015;5:10180. doi: 10.1038/srep10180.
30. Sénémaud J, Caligiuri G, Etienne H, Delbosc S, Michel JB, Coscas R. Translational relevance and recent advances of animal models of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2017;37:401-410. doi: 10.1161/ATVBAHA.116.308534.
31. Abdul-Hussien H, Soekhoe RG, Weber E, von der Thüsen JH, Kleemann R, Mulder A, van Bockel JH, Hanemaaijer R, Lindeman JH. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol. 2007;170:809-817. doi: 10.2353/ajpath.2007.060522.
32. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110:625-632. doi: 10.1172/JCI15334.
33. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atheroscle-rotic plaque but reduced aneurysm formation in mice with strome-lysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440-1445.
34. Nagashima H, Aoka Y, Sakomura Y, Uto K, Sakuta A, Aomi S, Kurosawa H, Hagiwara N, Kawana M, Kasanuki H. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg. 2004;39:447-453. doi: 10.1016/j.jvs.2003.07.005.
35. Flondell-Sité D, Lindblad B, Kölbel T, Gottsäter A. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokine. 2009;46:211-215. doi: 10.1016/j.cyto.2009.01.007.
36. Flondell-Sité D, Lindblad B, Gottsäter A. Patterns of markers of inflammation, coagulation and vasoconstriction during follow-up of abdominal aortic aneurysms. Int Angiol. 2012;31:276-282.
37. Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P, Meilhac O, Guillin MC, Michel JB. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006;168:1022-1030. doi: 10.2353/ajpath.2006.050868.